Clinical trial

Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)

Recruiting now · Not applicable · 1 countries · Registry ID NCT06783751

Recruiting nowNot applicableInterventional

What this study is about

This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 65 Years
SexAll
Healthy volunteersNot accepted
ConditionObesity, Bariatric Surgery, Sleeve Gastrectomy, Gastroesophageal Reflux Disease

Full registry criteria

Inclusion Criteria: 1. Male and female subjects aged 18-65 years 2. Body mass index (BMI) 35-55 kg/m2 3. Must meet the BMI criteria before and after 6 months of nonsurgical weight management 4. Presence of GERD defined for this trial as acid exposure time (AET) of 4.9% or above as assessed with the Bravo pH test. 5. Have health insurance which pays for the costs of bariatric surgery and standard medical care before and after surgery 6. Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry and prior to surgery 7. Must be able to provide written informed consent Exclusion Criteria: 1. Hiatal hernia \>2cm (defined as maximum axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at the time of surgery) 2. Evidence of clinically significant major esophageal motility disorder as determined by the site primary investigator 3. Severe gastroparesis 4. Previous bariatric or anti-reflux procedure 5. Barrett's esophagus 6. Subjects requiring mesh treatment at time of procedure 7. Severe heart (e.g., severe heart failure, unstable coronary artery disease), or end-stage lung disease as determined by the site primary investigator 8. Subjects with pacemakers, implantable defibrillators, neurostimulators 9. Portal hypertension or cirrhosis 10. Chronic pancreatitis 11. Active cancer treatment 12. Inability to tolerate general anesthesia 13. Uncontrollable coagulopathy 14. Significant and uncontrolled inflammatory bowel disease 15. Severe and/or uncontrolled psychiatric disorder (including psychosis, bipolar disorder) as determined during standard pre-surgery psychiatric screening at the site. 16. Suicidal ideation or unstable/untreated major depressive disorder within the past year 17. Alcohol or substance use disorder within the past year. 18. Pregnant or breastfeeding or planning pregnancy in the coming 24 months 19. Diminished intellectual capacity to consent or follow pre- and post-surgery instructions 20. History of, or any current health condition that, in the opinion of the PI, would make the subject ineligible for sleeve gastrectomy, or put the subject at risk by participation in the study.

Treatments and study arms

Modified Vertical Sleeve Gastrectomy (mVSG)

Procedure

The modified procedure preserves the gastric sling fibers and re-establishes the gastroesophageal flap valve (GEFV).

Conventional Vertical Sleeve Gastrectomy (cVSG)

Procedure

Vertical Sleeve Gastrectomy as standard procedure

Primary outcomes

% Acid Exposure Time (%AET)Pre-surgery, Month 6-9 post surgery

Change in %AET in percentage points at Month 6-9 relative to pre-surgery %AET assessed with the Bravo pH test

Study locations

2 locations were listed when this page was built. The first 40 are shown.

University of California, Irvine🇺🇸 Orange, California, United States
Ninh T. Nguyen, MDContact
Cesar Figuerosa, BSContact
University of California, San Diego🇺🇸 San Diego, California, United States
Ravinder K. Mittal, MDContact